Directed Engagement Of Activating Fc Receptors
AssigneeMassachusetts Institute of Technology
InventorsK. Dane Wittrup, Shanshan Wu Howland
Life of this patent
Estimating the term…
Abstract
The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR.
Claims23
1-50. (canceled)
An isolated nucleic acid comprising a sequence encoding a protein comprising a variant fibronectin 3 (Fn3) domain amino acid sequence that is at least 70% identical to SEQ ID NO:1 and specifically binds an activating Fc gamma receptor IIA or IIIA, wherein the variant Fn3 domain comprises the amino acid sequence of the BC domain, the DE domain, and the FG domain of any one of any one of SEQ ID NOs:
- 2-35.
(canceled)
A method of treating a patient diagnosed as having cancer, the method comprising administering to the patient the engineered protein encoded by the nucleic acid of claim 59, wherein the polypeptide that specifically binds a cellular target is a part of an immunoglobulin that specifically binds a cancer antigen expressed in the patient.
57-58. (canceled)
An isolated protein comprising a variant fibronectin 3 (Fn3) domain amino acid sequence that is at least 70% identical to SEQ ID NO:1 and specifically binds an activating Fc gamma receptor IIA or IIIA, wherein the variant Fn3 domain comprises the amino acid sequence of the BC domain, the DE domain, and the FG domain of any one of any one of SEQ ID NOs:
- 2-35.
Dependencies are inferred from the claim text.